Dehydroepiandrosterone supplementation in elderly men: A meta-Analysis study of placebo-controlled trials

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages 3615-3626

  Corona, Giovanni ^a   Rastrelli, Giulia ^b   Giagulli, Vito A ^c   Sila, Annamaria ^a   Sforza, Alessandra ^c   Forti, Gianni ^b   Mannucci, Edoardo ^d   Maggi, Mario ^a  

^a Azienda USL di Bologna   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Unit of Metabolic Diseases and Endocrinology   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PLACEBO; PRASTERONE; TESTOSTERONE;

AGED; ARTICLE; BODY COMPOSITION; BONE; DEHYDROEPIANDROSTERONE DEFICIENCY; ESTRADIOL BLOOD LEVEL; FAT MASS; FOLLOW UP; GLUCOSE METABOLISM; HORMONE DEFICIENCY; HUMAN; LIPID METABOLISM; MALE; META ANALYSIS; METABOLISM; METABOLITE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL FUNCTION; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

AGED; BODY COMPOSITION; BONE AND BONES; CONTROLLED CLINICAL TRIALS AS TOPIC; DEHYDROEPIANDROSTERONE; DIETARY SUPPLEMENTS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE;

EID: 84883654697     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1358     Document Type: Article

References (65)

1. Butenandt A, Dannenbaum H. Isolierung eines neuen, physiologisch unwirksamen Sterinderivates aus Mannerharn, seine Verknupfung mit Dehydro-Androsteron und Androsteron.ZPhysiol Chem. 1934; 229:192-195.
2. Munson L, Gallagher TF, Koch FC. Isolation of dehydroisoandrosterone sulfate from normal male urine. J Biol Chem. 1944; 152:67-77.
3. Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders,GHdisorders, andDHEA).J SexMed. 2013;10:661-677.
4. Traish AM, Kang HP, Saad F, Guay AT. Dehydroepiandrosterone (DHEA): a precursor steroid or an active hormone in human physiology. J Sex Med. 2011;8:2960-2982; quiz 2983.
5. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97-148.
6. Araujo AB, Wittert GA. Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab. 2011;25:303-319.
7. Kushnir MM, Blamires T, Rockwood AL, et al. Liquid chromatography- tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem. 2010;56:1138-1147.
8. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-Analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676-3681.
9. Davis SR, Panjari M, Stanczyk FZ. DHEA replacement for postmenopausal women. J Clin Endocrinol Metab. 2011;96:1642-1653.
10. Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev. 2006;18: CD006221.
11. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.0.1. The Cochrane Collaboration; 2008. www.cochrane-handbook.org. Updated September 2008.
12. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 1988;66:57-61.
13. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360-1367.
14. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Potential remedial effects. Ann N Y Acad Sci. 1995;774:128-142.
15. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-Advanced men and women. Clin Endocrinol (Oxf). 1998;49:421-432.
16. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab. 1999;84:1527-1533.
17. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999;53:590-594; discussion 594-595.
18. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000; 97:4279-4284.
19. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab. 2001;86: 4686-4692.
20. van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology. 2001;26:591-612.
21. Kahn AJ, Halloran B, Wolkowitz O, Brizendine L. Dehydroepiandrosterone supplementation and bone turnover in middle-Aged to elderly men. J Clin Endocrinol Metab. 2002;87:1544-1549.
22. Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthymenwith age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male. 2003;6:151-156.
23. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003;88:3190-3195.
24. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004;292:2243-2248.
25. Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab. 2006;91:2986-2993.
26. Martina V, Benso A, Gigliardi VR, et al. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol (Oxf). 2006;64:260-264.
27. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355: 1647-1659.
28. Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. Am J Physiol Endocrinol Metab. 2006;291:E1003-E1008.
29. JankowskiCM,Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, KohrtWM.Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab. 2008;93: 4767-4773.
30. von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008;19:699-707.
31. Kritz-Silverstein D, von Mühlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc. 2008;56:1292-1298.
32. Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male. 2009;12:104-112.
33. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009;89:1459-1467.
34. Srinivasan M, Irving BA, Frye RL, et al. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men. J Clin Endocrinol Metab. 2010;95:1617-1625.
35. Jankowski CM, Gozansky WS, Van Pelt RE, Wolfe P, Schwartz RS, Kohrt WM. Oral dehydroepiandrosterone replacement in older adults: effects on central adiposity, glucose metabolism and blood lipids. Clin Endocrinol (Oxf). 2011;75:456-463.
36. Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3:533-542.
37. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest. 2011;34:557-567.
38. Corona G, Mannucci E, Forti G, Maggi M. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? Int J Androl. 2009;32:431-441.
39. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25:337-353.
40. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8:131-143.
41. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-Associated hypogonadotropic hypogonadism: a meta-Analytic study. Eur J Endocrinol. 2103;168(6):829-843.
42. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-Analysis study. J Sex Med. 2011;8:272-283.
43. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-Analysis study. Int J Androl. 2011;34:528-540.
44. Groth KA, Skakkebæk A, Host C, Gravholt CH, Bojesen A. Klinefelter syndrome: a clinical update. J Clin Endocrinol Metab. 2013;98:20-30.
45. Forti G, Corona C, Vignozzi L, Krausz C, Maggi M. Klinefelter's syndrome: a clinical and therapeutical update. Sex Dev. 2010;4: 249-258.
46. Lenzi A, Balercia G, Bellastella A, et al. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest. 2009;32:934-938.
47. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93:139-146.
48. Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol. 2009;5:559-568.
49. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol Endocrinol Metab. 1999;276:E317-E325.
50. Elbers JM, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003;58:562-571.
51. Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43:1016-1021.
52. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-Analytic study. Eur J Endocrinol. 2011;165:687-701.
53. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519-1524.
54. Legrain S, Berr C, Frenoy N, Gourlet V, Debuire B, Baulieu EE. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology. 1995;41:343-351.
55. Tilvis RS, Kähönen M, Härkönen M. Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano). 1999;11:30-34.
56. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart dis ease in middle-Aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001;153:79-89.
57. Kähönen MH, Tilvis RS, Jolkkonen J, Pitkälä K, Härkönen M. Predictors and clinical significance of declining plasma dehydroepiandrosterone sulfate in old age. Aging (Milano). 2000;12:308-314.
58. Sanders JL, Boudreau RM, Cappola AR, et al. Cardiovascular disease is associated with greater incident dehydroepiandrosterone sulfate decline in the oldest old: the cardiovascular health study all stars study. J Am Geriatr Soc. 2010;58:421-426.
59. Wang L, Wang YD, Wang WJ, Zhu Y, Li DJ. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-Activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol. 2007;38:467-479.
60. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
61. Basar MM, Aydin G, Mert HC, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005;66:597-601.
62. Vignozzi L, Corona G, Petrone L, et al. Testosterone and sexual activity. J Endocrinol Invest. 2005;28:39-44.
63. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8:639-654; quiz 655.
64. Libe R, Barbetta L, Dall'Asta C, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest. 2004;27:736-741.
65. Liu TA, Liu MC, Yang YS. Immunohistochemical analysis of a novel dehydroepiandrosterone sulfotransferase-like protein in Drosophila neural circuits. Biochem Biophys Res Commun. 2008;367:14-20.